Background. Increasingly, it is being appreciated that B cells have broad roles beyond the humoral response and are able to contribute to and regulate inflammation. The specific role of B cells in the pathogenesis of early allograft inflammation remains unclear. Methods. To address this question, we generated B cell-deficient (B −/− ) Lewis rats via clustered regularly interspaced short palindromic repeats (CRISPR) technology. In a full mismatch transplant model, kidneys from Brown Norway donors were transplanted into B −/− Lewis recipients or wild type Lewis recipients. T cell-mediated rejection was attenuated with cyclosporine. Results. Renal inflammation was reduced at 1 week after transplant (Banff scores for interstitial inflammation, microvascular inflammation, glomerulitis, and C4d) in allografts from B −/− recipients. The reduction in interstitial inflammation was predominantly due to a decline in graft infiltrating macrophages. Intragraft T-cell numbers remained unchanged. In addition, B-cell deficiency was associated with increased T regulatory cells and reduced splenic T follicular helper cells at baseline; and significantly increased intragraft and splenic IL-10 mRNA levels after transplant. In vitro, B −/− and wild type splenic T cells produced similar levels of IFN-γ in response to T cell-specific activation. Conclusions. B-cell deficiency in this model produced an anti-inflammatory phenotype with a shift toward regulatory T-cell populations, production of antiinflammatory cytokines (IL-10), and a reduction in allograft inflammation. These findings define a role for B cells to influence the cell populations and mediators involved in the pathogenesis of early allograft inflammation.
A lthough we have made great gains in the understanding and treatment of allograft inflammation and acute rejection, it is also clear that there are gaps in our understanding of key immunologic mechanisms involved. Furthermore, our current immunosuppressive regimen does not effectively target all inflammatory cells (macrophages, plasma cells) or immune responses (complement system). Although therapeutics targeted to these inflammatory cells and immune systems are now available, they typically do not comprise the backbone of standard immunosuppressive therapy in transplantation. Traditionally, induction therapy is directed at T cells to reduce acute cellular rejection; whether this approach translates into a long-term benefit of increasing allograft survival remains unclear.
Although the idea that B cells have functions beyond the humoral response is gaining recognition, their specific role in the pathogenesis of early allograft inflammation and acute rejection remains unclear. Several clinical studies of acute cellular rejection demonstrate patient biopsies with graft infiltrating B cells (CD20 + ) correlate with a higher incidence of steroid resistant rejection and reduced graft survival compared with patients lacking CD20 + cell infiltrates. [1] [2] [3] Others, however, found no difference in steroid resistance or graft loss at 1 year in patients with acute cellular rejection based on the presence or absence of CD20 + cell infiltrates. 4, 5 In a randomized clinical trial of patients diagnosed with acute rejection and graftinfiltrating B cells, anti-B-cell therapy with rituximab was associated with improved graft function and rejection score on biopsy at 6 months but without effect on donor-specific antibody (DSA). 6 In contrast, another randomized clinical trial of a single dose of rituximab at induction showed no effect on steroid resistance or on graft survival at 4 years. 7 Clinically, B cells have been identified in patients with acute rejection; however, trials with anti-B-cell therapy have provided conflicting results.
To elucidate the role of B cells in allograft rejection, numerous methods to manipulate B cells and antibodies have been used in both mouse and rat studies. A genetic model of immunoglobulin-deficient mice in a cardiac rejection model demonstrated reduced acute rejection and prolonged survival. 8 Another cardiac rejection model in severe combined immunodeficiency mice (SCID, lacking B and T cells) showed recipients failed to develop vasculopathy of rejection. 9 In a full mismatch mouse kidney transplant model, B cell depletion by treatment with an anti-CD19 antibody-reduced pathologic lesions of interstitial inflammation, tubulitis, and tubular atrophy at 21 days, which translated into reduced mortality in the treated recipients at 100 days. 10 Others have used a genetic B cell-deficient (B
−/−
) rat in a model of cardiac rejection, in which the heavy chain of IgM was targeted. Since membrane immunoglobulin expression is mandatory for normal B cell maturation, this genetic modification results in a very early block of B cell production. The immunoglobulin heavy chain-deficient rats failed to develop hyperacute allograft rejection in a sensitized cardiac transplant model. 11 However, there is limited information in the literature detailing renal allograft and lymphoid tissue pathology in these models.
Despite some advantages to conducting experimental studies in genetically modified mice, there are significant limitations to mouse kidney transplant experiments. Limitations of mouse kidney transplant experiments include the relative ease of inducing tolerance, resistance of many mouse strains to glomerulosclerosis and immune-mediated injury, and the weaker complement system in the mouse. 12, 13 These limitations, plus the technical surgical challenges in performing kidney transplants in mice, make the rat model more reproducible and clinically relevant. 14 We sought to examine the specific role of B cells in early allograft inflammation in a fully mismatched rat kidney transplant model using a genetically modified recipient with complete B cell deficiency. Kidney allografts were assessed for graft infiltrating inflammatory cells and regulatory phenotypes.
MATERIALS AND METHODS

Development of B
−/− Rat Strain B −/− Lewis rats were generated via clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 technology by targeting Igh6, the rat gene ortholog of IgM. More specifically, the N-terminal portion of the Igh6 constant domain (CH1) was selected. This region is highly conserved among human, mouse, and rat IgM. Therefore, a deletion was generated at this location as it was ensured to reside within the well-characterized constant region of IgM. Cas9 mRNA and guide RNA were microinjected into the cytoplasm of Lewis embryos and the embryos were transplanted into recipient females. A founder rat carrying the 8-basepair deletion was selected to generate a breeding colony. DNA from progeny ear punches were sequenced and genotyped.
Cell Phenotyping
Single cell suspensions of splenocytes, bone marrow, and lymph node cells were stained for B and T cells and analyzed by flow cytometry (BD LSR II at the UWCCC Flow Cytometry Laboratory) using FlowJo software (TreeStar) as previously described. 15 Serum levels of IgM and IgG were determined by EnzymeLinked Immunosorbent Assay (ELISA) according to manufacturers' instructions (Affymetrix, Inc.). Blood urea nitrogen (BUN) and serum creatinine measurements were determined by automated analysis (VetTest Analyzer Technology).
For IgM and IgG Enzyme-Linked ImmunoSpot (ELISPOT) assay, splenoctyes were incubated overnight on a plate coated with capture antibody (anti-IgM, or anti-IgG antibody). Plates were washed and incubated with biotinylated anti-IgM or anti-IgG antibody. Then plates were washed and incubated with streptavidin-alkaline phosphatase conjugate. The plates were developed with BCIP/NBT substrate (MabTech) until distinct spots appeared. Color development was stopped by extensively washing with water. After drying, spots were quantified through a dissecting microscope.
For IFN-γ ELISPOT assay, splenocytes were incubated overnight at 37°C with media or the stimulant Concanavalin A (final concentration, 10 μg/mL; Vector Labs). After incubation, plates were washed and IFN-γ biotinylated antibody was added (R&D Systems). After incubation with streptavidinalkaline phosphatase conjugate, plates were developed with BCIP/NBT substrate. Once spots formed, development was stopped by flooding plates with water and allowed to dry. Spots were quantified by plate reader (AID).
Rat Kidney Transplant Model
All Brown Norway and Lewis rats (Harlan Laboratories) were housed under pathogen free conditions in the animal care facility of the William S. Middleton VA Hospital (Madison, WI). All procedures were performed in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and the Public Health Service Policy on Humane Care and Use of Laboratory Animals. Full mismatch allogeneic kidney transplants were performed with Brown Norway kidney donors to B −/− Lewis recipients (N = 7) or Brown Norway donors to wild type (WT) Lewis recipients (N = 6). To avoid graft loss from severe T cell mediated acute rejection, all recipients were given cyclosporine (10 mg/ kg/day) via intraperitoneal injection until harvest at 7 days. See In-Depth Methods (SDC, http://links.lww.com/TP/B506) for a complete description of transplant microsurgery.
Histology
Kidney and splenic tissues were fixed in formalin, embedded in paraffin, cut into 5-μm sections, stained with hematoxylin and eosin or periodic acid-Schiff stain, and evaluated by light microscopy. Histologic analysis was scored by a transplant pathologist blinded to study groups (W.Z.) according to Banff 2013 criteria. 16 High-powered images were obtained on an Olympus BX51 microscope with an Olympus KP70 camera and software (Olympus America Inc.).
Immunohistochemistry, Immunofluorescence Microscopy, and Immunoblotting
Immunoperoxidase, immunofluorescence stain, and Western blot were performed as previously described. 17, 18 The following antibodies were used: polyclonal anti-C4d (American Research Products), polyclonal anti-CD3 (Abcam), anti-CD68 (clone ED1; Biorad), anti-PAX5 (clone A-11; Santa Cruz), and anti-glyceraldehyde 3-phosphate dehydrogenase (clone 6C5; Abcam).
Reverse Transcriptase Polymerase Chain Reaction Analysis
Total RNA was extracted from frozen kidney tissue with Trizol (Life Technologies) and purified using the RNAeasy kit (Qiagen). cDNA was generated with SuperScript IV first-strand synthesis system (Invitrogen). TaqMan gene expression assays (Applied Biosystems) were run on a 7500 Reverse Transcriptase polymerase chain reaction (PCR) System (Applied Biosystems). C T , standard deviation, and ΔΔ C T (compared with glyceraldehyde 3-phosphate dehydrogenase control) were used to calculate fold changes.
Statistical Analyses
Data were analyzed using GraphPad Prism software. Student t test or Mann-Whitney rank sum test were used to compare parametric and nonparametric continuous data. Fisher exact or χ 2 tests were used to compare categorical data. Correlations were determined by Pearson correlation test. A P value less than 0.05 was considered significant.
RESULTS
Characterization of B
−/− Rat Strain CRISPR/Cas9 targeting technology was used to generate B −/− Lewis rats. A targeted deletion of the Igh6 constant region (CH1) was performed ( Figure 1A ). This region is upstream of the gene sequences for the variable regions and is highly conserved among human, mouse, and rat ( Figure 1B) . The Cas9 target sequence and cut site is shown in Figure 1C . Characterization of the recovered nonsense allele demonstrated an 8-basepair deletion resulting in an early truncation of IgM ( Figure 1D ). To confirm the phenotype of our B −/− strain, we examined B cell and immunoglobulin expression in bone marrow, secondary lymphoid organs, and circulating blood. Analysis of B-cell populations in bone marrow and spleen by flow cytometry demonstrated the absence of B-cell populations ( (Table 1 , P = 0.007). Glomerulitis (P = 0.002), microvascular inflammation (P = 0.006), and C4d staining (P = 0.005) were also significantly reduced in B −/− compared with WT (Table 1) . after transplant compared with baseline ( Figure 9A and B) (P = 0.01 and P < 0.001, respectively).
DISCUSSION
We investigated the effect of complete B cell deficiency on allograft inflammation in a rat kidney transplant model. This study found attenuated renal inflammation in the allografts of B −/− recipients at 1 week after transplant as evidenced by reduced interstitial inflammation, glomerulitis, microvascular inflammation, and C4d deposition. The reduction in interstitial inflammation was mainly due to a decrease in graft infiltrating macrophages, as the levels of intragraft T cells were similar. B −/− rats displayed an increased number of splenic Treg cells and decreased Tfh cells at baseline. After transplant, B −/− rats demonstrated increased levels of the anti-inflammatory cytokine IL-10 in the spleen and allograft. In aggregate, these findings suggest that crosstalk between B cells, T cells, and macrophages is critical to the development of allograft inflammation. It also underscores the importance of studies targeting the regulatory role of the innate system in transplantation.
We found a reduction in interstitial inflammation in the allografts of B −/− recipients due to a reduction in intragraft macrophages. Interstitial inflammation due to intragraft macrophages has gained recent attention as it correlates with severity of rejection, development of interstitial fibrosis, and graft loss. [19] [20] [21] [22] [23] A recent study demonstrated interstitial inflammation in early protocol biopsies due to CD68 + macrophages, but not CD3 + T cells or CD20 + B cells, was associated with eGFR decline at 4 years. 21 Thus, intragraft macrophages appear to play a role in allograft pathology and have an important role in contributing to long-term allograft outcomes. Others have shown the majority of intragraft CD68-positive cells were also positive for HLA-DR. 20 This finding provides a link between innate and adaptive immunity, with a mechanism for binding and presenting antigen by macrophages. Macrophages are routinely categorized in subsets as classically activated, M1, or alternatively-activated, M2. However, limitations of the M1-M2 paradigm are increasingly being appreciated. The plasticity of macrophages in response to their microenvironment is substantial; with the ability to moderate Th1, Th2, inflammatory, fibrotic, and reparative responses. 24 The lack of available reagents in rat models to characterize inflammatory cells continues to be an obstacle, but work is ongoing to better define macrophage phenotypes and to standardize experimental conditions to study macrophage biology. 24 In clinical and preclinical studies, macrophages are emerging as having an important role in the inflammatory and reparative processes in ischemia-reperfusion and rejection.
We found significant reductions in many of the pathologic features often associated with acute antibody-mediated rejection in the allografts from B −/− recipients. Specifically, we observed decreased glomerulitis, microvascular inflammation, and C4d deposition. The time course for this model was only 1 week, at which point, we would not expect to see a major contribution from an allospecific antibody response. Thus, the presence of early-onset pathologic features typically associated with antibody-mediated rejection raises the possibility of immune injury from a nonallospecific antibody source. One such candidate for nonallospecific antibody-mediated injury is natural antibodies. Natural antibodies exist in the circulation of healthy individuals and are produced without previous antigen exposure or immunization. In previous studies, we demonstrated a role for natural antibodies to cause renal injury via the complement system and promote glomerulosclerosis in murine models of glomerular disease. 25, 26 Others have demonstrated contributions from . natural antibodies to complement activation and clearance of apoptotic cells. [27] [28] [29] A role for natural antibodies in rejection is now being investigated clinically. Circulating natural antibodies have been identified in patients with acute rejection and were associated with graft loss. [30] [31] [32] The pathologic role of nonallospecific antibodies in transplantation is an exciting line of research with future clinical implications. B −/− rats displayed an anti-inflammatory phenotype in this model. At baseline, B −/− rats had increased splenic Treg cell and decreased Tfh cell populations. Splenic germinal center formation arises from bidirectional interaction between Tfh cells and B cells. [33] [34] [35] [36] Ultimately, the recognition of cognate alloantigen by Tfh and B cells within germinal centers results in the generation of memory B cells, long-lived plasma cells, and DSA production. 33, 37 The clinical significance of Tfh cells kidney transplant patients has recently been reported. Patients with high levels of circulating Tfh cells also had high levels of preexisting DSA, indicating a role for Tfh cells in the anti-donor response and rejection. 38 The role of B cells to modulate Tfh cells is of interest, as ways to alter Tfh cells in transplant as a potential therapeutic target are under study. 39 After transplant, we observed increased levels of the regulatory cytokine IL-10 in B −/− recipients, but similar IFN-γ production. IL-10 is known to be produced by monocytes, T cells, and B cells. Clinically, it has been shown that cytokine polarization with low anti-inflammatory cytokine (IL-10) production and increased proinflammatory cytokines (IFN-γ or TNF-α) is associated with graft dysfunction and poor graft outcomes. [40] [41] [42] Additionally, studies have demonstrated the importance of IL-10 in tolerant renal transplant recipients. Tolerant recipients had increased levels of B cells producing IL-10 and had an enhanced ability to produce IL-10 compared with healthy controls. 43 In sum, B cell deficiency in this model produced an anti-inflammatory phenotype with presence of regulatory cell populations and production of antiinflammatory mediators.
Our study has several limitations. We used a genetic model of complete B cell deficiency and some of our results differ from what has been observed in clinical studies. Potential reasons for these differences may stem from difficulty in eliminating antibody producing plasma cells in clinical studies and the lack of reduction of DSA in patients treated with rituximab. 6 ,44 B-cell depletion by rituximab provides good systemic B cell depletion. However, its effect on B cell depletion in secondary lymphoid tissues, such as spleen and lymph nodes, is less effective. 45, 46 Our genetic model of complete B-cell deficiency differs in this regard, as no B-cell populations were seen in circulation or lymphoid tissues. Future studies are needed in this model examine the effect of complete B cell deficiency in chronic rejection. However, the current model allowed us to study the role of B cells in acute rejection without interference by repopulation of B cells or alterations in B-cell mediators or cytokines.
The current study demonstrates B cells play a key role in exacerbating allograft inflammation and macrophage infiltration. B-cell deficiency was associated with an antiinflammatory phenotype with a shift toward populations of Treg cells, a reduction in Tfh cells, and production of anti-inflammatory cytokines (IL-10). Further studies are needed to better understand the regulatory role of each arm of the immune system to improve preventative and therapeutic strategies for allograft injury.
